News for Orphazyme A/S Stock (ORPH)

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 07/20/21

BREAKING NEWS: TOP RANKED ROSEN LAW FIRM Encourages Orphazyme A/S Investors With Losses Over $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action - ORPH

Newsfile Corp • 07/19/21

ORPH Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Orphazyme A/S Shareholders of Class Action and Encourages Shareholders to Contact the Firm

Business Wire • 07/19/21

EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Orphazyme A/S Investors With Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH

Business Wire • 07/17/21

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Orphazyme A/S (ORPH) Investors

Business Wire • 07/16/21

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Orphazyme A/S (ORPH) Investors

Business Wire • 07/16/21

SHAREHOLDER ALERT: Robbins LLP Announces that Orphazyme A/S (ORPH) is Being Sued for Misleading Shareholders

Business Wire • 07/16/21

Orphazyme Stock Is a Dead-End for Investors After FDA Rejection

InvestorPlace • 07/16/21

The Law Offices of Frank R. Cruz Announces Investigation of Orphazyme A/S (ORPH) on Behalf of Investors

Business Wire • 07/15/21

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Orphazyme A/S (ORPH) on Behalf of Investors

Business Wire • 07/15/21

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Orphazyme A/S (ORPH) on Behalf of Investors

Business Wire • 07/15/21

ORPH INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Orphazyme A/S

PRNewsWire • 07/15/21

ROSEN, A LONGSTANDING AND TRUSTED LAW FIRM, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - ORPH

PRNewsWire • 07/14/21

DEADLINE FOR ORPH INVESTORS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Orphazyme A/S

Newsfile Corp • 07/14/21

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important Deadline – ORPH

Business Wire • 07/13/21

ORPH Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Orphazyme A/S Shareholders of Class Action and Encourages Shareholders to Contact the Firm

PRNewsWire • 07/13/21

ORPHAZYME ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Orphazyme A/S and Encourages Investors to Contact the Firm

Business Wire • 07/13/21

ORPHAZYME INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Orpahzyme A/S Class Action Lawsuit - ORPH

Business Wire • 07/12/21

Pomerantz Law Firm Announces the Filing of a Class Action Against Orphazyme A/S and Certain Officers and Directors - ORPH

PRNewsWire • 07/10/21

Orphazyme's Massive Price Appreciation Won't Be Captured Again

InvestorPlace • 07/08/21

Orphazyme A/S May Look Like a Long Shot, but Things Aren't That Dire

InvestorPlace • 07/07/21

Despite FDA Disappointment, All Hope Isn't Lost for Orphazyme

InvestorPlace • 07/01/21

2 Underperforming Stocks to Sell

GuruFocus • 06/30/21

CytRx Comments on Orphazyme's Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C

Business Wire • 06/30/21

ORPH Stock: The Big News That Has Red-Hot Orphazyme Gaining Today

InvestorPlace • 06/29/21